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Saxagliptin, a potent and selective DPP-4 inhibitor, is characterized by its slow dissociation from DPP-4
and its long half-life and is expected to have a potent tissue membrane-bound DPP-4-inhibitory effect in
various tissues. In the present study, we examined the effects of saxagliptin on in situ cardiac DPP-4
activity. We also examined the effects of saxagliptin on isoproterenol-induced the changes in the early
stage such as, myocardial remodeling and cardiac diastolic dysfunction. Male SD rats treated with
isoproterenol (1 mg/kg/day via osmotic pump) received vehicle or saxagliptin (17.5 mg/kg via drinking
water) for 2 weeks. In situ cardiac DPP-4 activity was measured by a colorimetric assay. Cardiac gene
expressions were examined and an echocardiographic analysis was performed. Saxagliptin treatment
signiﬁcantly inhibited in situ cardiac DPP-4 activity and suppressed isoproterenol-induced myocardial
remodeling and the expression of related genes without altering the blood glucose levels. Saxagliptin
also signiﬁcantly ameliorated cardiac diastolic dysfunction in isoproterenol-treated rats. In conclusion,
the inhibition of DPP-4 activity in cardiac tissue by saxagliptin was associated with suppression of
myocardial remodeling and cardiac diastolic dysfunction independently of its glucose-lowering action in
isoproterenol-treated rats. Cardiac DPP-4 activity may contribute to myocardial remodeling in the
development of heart failure.
© 2016 Kyowa Hakko Kirin Co.,Ltd. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease is a major cause of morbidity and mor-
tality in patients with type 2 diabetes mellitus (T2DM) (1).
Although diabetic microvascular complications have been shown to
be reduced by strict glycemic control, it is not clear whether strict
glycemic control can reduce macrovascular complications in dia-
betes patients (2e5).
Myocardial remodeling, including cardiac hypertrophy and
ﬁbrosis, plays an important role in cardiovascular disease, and is an
independent risk factor for cardiovascular events (6,7). Diabetes
mellitus is associated with increased myocardial remodeling, and
classical or new generation antidiabetic agents have been reportedS. Kunori).
rmacological Society.
ion and hosting by Elsevier B.V. on
enses/by-nc-nd/4.0/).to ameliorate myocardial remodeling via both glucose-dependent
and glucose-independent actions in various animal models of
heart failure (8).
Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glucose
metabolism by preventing the degradation of incretin hormones,
such as glucagon-like peptidase-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP). While these agents
have been used in the treatment of T2DM, a meta-analysis of
randomized clinical trials showed that DPP-4 inhibition reduced
the risk of cardiovascular events and all-cause mortality in pa-
tients with T2DM (9). Furthermore, recent animal studies
demonstrated that DPP-4 inhibition ameliorated cardiac
dysfunction and myocardial remodeling in non-diabetic animal
models of cardiovascular injury (10,11).
Saxagliptin, a potent and selective DPP-4 inhibitor, is linked to
DPP-4 by a covalent bond and is characterized by its slow dissoci-
ation from DPP-4 and long half-life (12). Saxagliptin is therefore
expected to have a potent tissue membrane-bound DPP-4behalf of Japanese Pharmacological Society. This is an open access article under the
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that saxagliptin exerts renoprotective effects through its potent
inhibitory effects on renal DPP-4 activities in Dahl salt-sensitive
hypertensive rats (13,14). In addition, a recent animal study
demonstrated that saxagliptin treatment improved cardiac
dysfunction in an experimental model of post-myocardial infarc-
tion without affecting the blood glucose level (15). In the present
study, we examined the effects of treatment with saxagliptin on in
situ cardiac DPP-4 activity and myocardial remodeling in a rat
model of isoproterenol-induced heart failure. In addition, we also
examined the effects of saxagliptin on isoproterenol-induced car-
diac diastolic dysfunction in rats. We obtained evidence that sax-
agliptin inhibited cardiac DPP-4 activity and was associated with an
improvement in myocardial remodeling and diastolic dysfunction
without glycemic action in isoproterenol-treated rats.
2. Materials and methods
2.1. Animals
Male eight-week-old SpragueeDawley (SD) rats (Charles River
Japan, Inc., Yokohama, Japan) were used. Prior to the experiments,
the rats were kept at 19e25 C in 30e70% humidity under a 12-h
lightedark cycle with ad libitum access to tap water and commer-
cial chow (FR-2; Funabashi Farm, Chiba, Japan). All of the animal
experiments were approved by the Committee for Animal Experi-
ments of Kyowa Hakko Kirin Co., Ltd. All of the animals received
humane care that complied with the Japanese Pharmacological
Society's “Guiding Principles for the Care and Use of Laboratory
Animals”.
2.2. Saxagliptin monohydrate
Saxagliptin monohydrate (saxagliptin) was obtained from Bris-
tol Myers Squibb (Pennington, NJ, USA). Saxagliptin was dissolved
in distilled water (0.02%w/w) and was administered to rats with
drinking water. The saxagliptin dose that was calculated from their
daily water consumption was approximately 17.5 mg/kg/day. The
dose was determined based on the ﬁndings of preliminary studies
indicating the inhibitory effect of 17.5 mg/kg of saxagliptin on the
plasma DPP-4 activity of rats.
2.3. Experimental procedures
Forty-ﬁve rats were divided into the following three groups: (1)
normal group (vehicle); (2) control group (vehicle); and (3) sax-
agliptin (approximately 17.5 mg/kg/day). Isoproterenol (1 mg/kg/
day) was administered for 2-weeks to all of the rats (except those in
the normal group) by a subcutaneously implanted osmotic mini-
pump (Alzet, model 2002; Durect, Cupertino, CA). Saxagliptin
treatment (via drinking water) was initiated at the same time. After
the 2-week treatment, the rats were anesthetized with 3% iso-
ﬂurane, blood samples were collected and their hearts were
removed. The weight of each heart was measured. The blood and
heart samples were used for the measurement of DPP-4 activity.
2.4. Echocardiography
At 2 weeks after the start of saxagliptin treatment, echocardi-
ography was performed in rats anesthetized with 3% isoﬂurane
using a 15 MHz ultrasound probe (MS200, VisualSonic, Tronto,
Canada) and an ultrasound imaging system (Vevo2100, VisualSonic,
Tronto, Canada). M-mode recordings were performed through the
left ventricular anterior and posterior wall at the level of the
papillary muscles to measure the left ventricular end-diastolicdimension (LVDd), left ventricular end-systolic dimension (LVDs),
fractional shortening (FS), left ventricular ejection fraction, left
ventricular posterior wall thickness (PWT) and the inter-
ventricular septum wall thickness (IVST). FS was calculated ac-
cording to the following formula:
FS ¼ [(LVDd  LVDs)/LVDd]  100
The LV mass was calculated according to the following formula:
LV mass ¼ 1.04  [(LVDd þ PWT þ IVST)3  (LVDd)3]
Pulse wave Doppler-mode recordings were performed to mea-
sure the peak early left ventricular ﬁlling wave (MVE), the peak late
or atrial ﬁlling wave velocity (MVA) and the E-wave deceleration
time (DT).2.5. The measurement of the plasma DPP-4 activity
The plasma samples were separated via centrifugation (1800g
for 20 min at 4 C). The rats' plasma DPP-4 activity levels were
measured using a ﬂuorometric assay with Gly-Pro-7-AMIDO-4-
METHYLCOUMARIN (Gly-Pro-AMC) (PEPTIDE INSTITUTE, Osaka,
Japan) substrate. A 25 mL volume of plasma diluted two-fold with
distilled water was mixed with 25 mL of assay buffer (25 mmol/L of
HEPES, 140 mmol/L of NaCl, 80 mmol/L of MgCl2/6H2O, 1 w/v% BSA,
pH 7.8). To exclude the non-speciﬁc amino peptidase activity,
plasma samples that were diluted two-fold with DPP-4 inhibitor-
containing solution (10 mmol/L saxagliptin) were also used. The
enzyme reactionwas initiated by adding 50 mL of substrate solution
(ﬁnal concentration: 50 mmol/L Gly-Pro-AMC), followed by incu-
bation for 20 min at room temperature. The reaction was then
terminated by adding 50 mL of 10% acetate solution. The ﬂuores-
cence intensity was measured using a Spectra Max M2e microplate
reader (Molecular Devices, Sunnyvale, USA) at an excitation wave
length of 460 nm and an emissionwave length of 390 nm. The DPP-
4 activity was expressed as the amount of AMC generated after
20 min of incubation.2.6. In situ cardiac DPP-4 activity
The in situ cardiac DPP-4 activity was measured in 5 rats of each
group. The left ventricular chambers were frozen and embedded in
OCT compound. The sections were cut using a cryostat and ﬁxed in
a mixture of formalin, phosphate buffer and acetone (ratio 1:35:15)
for 1 min, after which they were rinsed with distilled water for 30 s.
The ﬁxed sections were reacted with a mixture of Glycyl-prolyl-4-
methoxy-b-naphthylamide and Fast blue BN for 15min. The DPP-4-
positive regions in the left ventricle specimens were stained red.
DPP-4 activity was quantitatively expressed as the staining in-
tensity in the left ventricular tissue using the Aperio ImageScope
and Color Deconvolution version 9 software programs.2.7. Histological examination
The left ventricular chambers were ﬁxed in 10 vol% neutral
buffered formalin solution and embedded in parafﬁn. The parafﬁn-
embedded sections were then stained with Masson's trichrome to
quantify the extent of the myocardial and perivascular ﬁbrosis. The
myocardial or perivascular ﬁbrotic area was measured using the
Aperio ImageScope and Color Deconvolution ver. 9 software pro-
grams. The ratio of myocardial or perivascular ﬁbrosis in a ran-
domized area was calculated.
Table 1
The effects of saxagliptin on body weight, blood glucose, heart weights and plasma
DPP-4 activity in the isoproterenol-treated rats.
Normal Control Saxagliptin
Number 15 15 15
Body weight, g 395.5 ± 3.9 415.4 ± 2.3a 398.6 ± 4.1d
Heart weight, g 1.09 ± 0.02 1.46 ± 0.02a 1.33 ± 0.02d
Heart to body weight ratio, mg/g 2.76 ± 0.04 3.52 ± 0.05a 3.34 ± 0.06c
Serum glucose, mg/dL 145.0 ± 4.2 147.3 ± 4.1 142.3 ± 3.3
Plasma DPP-4 activity, pmol 855 ± 67 1130 ± 84b 113 ± 18c
The data represent the mean ± S.E.M. a: P < 0.01, b: P < 0.05 in comparison to the
normal group (Student's t-test). c: P < 0.05, d: P < 0.01 in comparison to the control
group (Student's t-test). Plasma DPP-4 activity was expressed as the amount of AMC
(pmol) generated after 20 min of incubation.
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Total RNA was extracted from heart tissue using an RNeasy
Fibrous Tissue Mini Kit (QIAGEN, Germantown, MD, USA). Total
RNA was reverse-transcribed using a SuperScript VILO cDNA Syn-
thesis Kit (Life Technologies, Carlsbad, CA, USA).
A quantitative real-time RT-PCR was performed using a Step
OnePLUS™ Real-Time PCR system (Applied Biosystems, Foster City,
CA, USA). The PCR primers were as follows: atrial natriuretic pep-
tide (ANP), 50-GATGGATTTCAAGAACCTGCTAGAC-30; Collagen I, 50-
AAAGGAGAACCCGGCCCTGCTGGAG-30; Collagen III, 50-GTCCT
GGTCCTGCAGGCCCTCCAGGACCTCC-30; interleukin-6 (IL-6), 50-
AATGAGAAAAGAGTTGTGCAATGGC-30; insulin-like growth factor-
1(IGF-1), 50-GCTTTTACTTCAACAAGCCCACAGG-30; 18s, 50-TACTTG
GATAACTGTGGTAATTCTA-30. 18s ribosomal RNA served as an in-
ternal control.2.9. Statistical analysis
All of the values are expressed as themean ± SEM. The statistical
analyses were performed using a The SAS software program
(release 9.2; SAS Institute, Inc., Cary, USA). The differences between
the normal and control groups, or the control and drug groups were0 
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Fig. 1. The effects of saxagliptin on in situ cardiac DPP-4 activity in isoproterenol-treate
(Student's t-test). Abbreviations: N.S., not signiﬁcant.assessed using Student's t-test or the AspineWelch test. P values of
<0.05 were considered to indicate statistical signiﬁcance.
3. Results
3.1. The effects on blood glucose and plasma DPP-4 activity
The blood glucose levels in the control and normal groups were
similar, and saxagliptin did not affect the blood glucose levels in the
isoproterenol-treated rats. Isoproterenol treatment signiﬁcantly
increased the plasma DPP-4 activity in comparison to the normal
group (855 ± 67 vs. 1130 ± 84 pmol; P < 0.05). Saxagliptin inhibited
the plasma DPP-4 activities of the isoproterenol-treated rats by 90%
(113 ± 18 pmol; P < 0.01 vs. the control group) (Table 1).
3.2. In situ cardiac DPP-4 activity
The DPP-4 activity in cardiac tissue was assessed by a colori-
metric assay. The endothelium of the venous part of the capillary
bed displayed DPP-4 activity and was stained red. The H-scores of
the staining intensity in the normal and control groups did not
differ to a statistically signiﬁcant extent (8.12 ± 2.12 vs. 5.16 ± 0.62).
Saxagliptin signiﬁcantly suppressed the cardiac DPP-4 activity of
the isoproterenol-treated rats (Fig. 1) (2.12 ± 0.21; P < 0.05 vs. the
control group).
3.3. The effects of saxagliptin on myocardial remodeling including
cardiac hypertrophy and ﬁbrosis, in isoproterenol-treated rats
The weight of the heart relative to the body weight indicated
that isoproterenol treatment induced cardiac hypertrophy in rats.
Saxagliptin signiﬁcantly suppressed the increase in the relative
weight of the heart in the isoproterenol-treated rats (Table 1). A
histopathological examination showed that the areas of myocardial
and perivascular ﬁbrosis in the left ventricle were signiﬁcantly
increased in the control group in comparison to the normal group.
Saxagliptin signiﬁcantly attenuated the increase in the perivascular
ﬁbrotic area and tended to attenuate the area of myocardial ﬁbrosistrol Saxagliptin
*
d rats. The data represent the mean þ S.E.M. (n ¼ 15). *: P < 0.01 vs. the control group
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Fig. 2. The effects of saxagliptin on the cardiac myocardium (A) and periven-
tricular (B) ﬁbrosis in isoproterenol-treated rats. The upper panel in A and B in-
dicates representative photomicrographs of cardiac sections stained with Masson's
trichrome. The data represent the mean þ S.E.M. (n ¼ 15). #: P < 0.01 vs. the normal
group (Student's t-test). *: P < 0.05 vs. the control group (Student's t-test).
Table 2
The effects of saxagliptin on cardiac gene expression in isoproterenol-treated rats.
Normal Control Saxagliptin
ANP, /r18s 0.75 ± 0.15 8.00 ± 1.2a 4.47 ± 1.05c
IL-6, /r18s 0.77 ± 0.05 3.63 ± 0.66a 2.09 ± 0.41c
IGF-1, /r18s 0.80 ± 0.07 1.56 ± 0.28b 1.16 ± 0.16
Collagen I, /r18s 1.01 ± 0.05 2.81 ± 0.47a 2.20 ± 0.47
Collagen III, /r18s 0.83 ± 0.05 2.26 ± 0.35a 1.72 ± 0.32
The data represent the mean ± S.E.M. a: P < 0.01, b: P < 0.05 in comparison to the
normal group (Student's t-test). c: P < 0.05 in comparison to the control group
(Student's t-test).
Table 3
The effects of saxagliptin on the echocardiographic parameters of isoproterenol-
treated rats.
Normal Control Saxagliptin
Heart rate, beats/min 354.5 ± 5.6 424.6 ± 8a 430.2 ± 10.9
LVDd, mm 8.06 ± 0.17 7.68 ± 0.16 7.21 ± 0.14
LVDs, mm 4.35 ± 0.14 2.24 ± 0.2a 2.07 ± 0.16
PWT, mm 2.47 ± 0.12 2.78 ± 0.09 2.86 ± 0.13
IVST, mm 2.81 ± 0.08 4.50 ± 0.1a 4.25 ± 0.13
EF, % 75.3 ± 1.5 94.0 ± 1.1a 94.0 ± 1.4
J. Ikeda et al. / Journal of Pharmacological Sciences 132 (2016) 65e7068in the isoproterenol-treated rats (Fig. 2). No areas of myocardial
infarction were observed in the isoproterenol-treated control and
saxagliptin groups. In the gene expression study, isoproterenol also
signiﬁcantly induced the expression of the ANP, IL-6, IGF-1, collagen
I and collagen III genes in cardiac tissue. Saxagliptin treatment
signiﬁcantly suppressed or tended to suppress the increased
expression of these genes (Table 2).FS, % 46.0 ± 1.5 71.2 ± 2.1a 71.2 ± 2.4
E/A, ratio 1.92 ± 0.06 1.47 ± 0.06a 1.68 ± 0.06b
DT, ms 36.8 ± 0.9 28.8 ± 1.4a 31.0 ± 1.4
LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic
dimension; PWT, left ventricular posterior wall thickness; IVST, inter ventricular
septum wall thickness; EF, left ventricular ejection fraction; FS, fractional short-
ening; E, peak early left ventricular ﬁlling wave; A, peak late or atrial ﬁlling wave
velocity; DT, E-wave deceleration time. The data represent the mean ± S.E.M. a:
P < 0.01 in comparison to the normal group (Student's t-test). b: P < 0.05 in com-
parison to the control group (Student's t-test).3.4. The effects of saxagliptin on the echocardiographic parameters
in isoproterenol-treated rats
The left ventricular end-systolic dimension (LVDs), inter-
ventricular septum wall thickness (IVST), fractional shortening
(FS) and LV mass were signiﬁcantly increased in the control group
after the 2-week administration of isoproterenol in comparison tothe normal group. There was no difference in the LVDs, IVST, FS or
LV mass values of the control and saxagliptin-treated groups. The
peak early left ventricular ﬁlling wave (MVE)/peak late or atrial
ﬁlling wave velocity (E/A) ratio and E-wave deceleration time (DT)
were signiﬁcantly decreased in the control group in comparison to
the normal group. Saxagliptin treatment signiﬁcantly ameliorated
the decrease in the E/A ratio in the isoproterenol-treated rats
(Table 3).
4. Discussion
In the present study, saxagliptin inhibited both in situ cardiac
DPP-4 activity staining and myocardial remodeling in a glucose-
independent manner in a rat model of isoproterenol-induced
heart failure. Furthermore, saxagliptin ameliorated isoproterenol-
induced cardiac diastolic dysfunction in rats. From these ﬁndings,
we hypothesize that the inhibition of DPP-4 activities in the cardiac
tissue by saxagliptin may suppress the myocardial remodeling
independently of its glucose-lowering action, and thereby amelio-
rate cardiac diastolic dysfunction in rats with isoproterenol-
induced heart failure.
In the present study, we measured the cardiac DPP-4 activity
using an in situ activity staining method and detected DPP-4
staining that was localized in the endothelium of the venous
capillary vessels in cardiac tissues. Saxagliptin signiﬁcantly inhibi-
ted cardiac DPP-4 activities in isoproterenol-treated rats. To our
knowledge, this is the ﬁrst study to demonstrate the suppressive
effect of DPP-4 inhibitor on in situ cardiac DPP-4 activity staining.
Saxagliptin treatment improves eNOS coupling in the aortic and
glomerular endothelium of animal models of hypertension (16).
Recent clinical studies have demonstrated that endothelial
dysfunction was closely associated with diastolic dysfunction in
patients with type 2 diabetes, chronic kidney disease or heart
J. Ikeda et al. / Journal of Pharmacological Sciences 132 (2016) 65e70 69failure (17e19). Saxagliptin might therefore exert a car-
dioprotective effect through a direct inhibitory action on cardiac
endothelial DPP-4 activities in isoproterenol-treated rats.
In the present study, saxagliptin treatment prevented the car-
diac hypertrophy and ﬁbrosis induced by the continuous infusion of
isoproterenol. This effect was accompanied by the suppressed
expression of genes related to hypertrophy, such as ANP, IL-6 and
IGF-1 and pro-ﬁbrotic factors, such as collagen I and collagen III.
Myocardial remodeling, including cardiac hypertrophy and ﬁbrosis,
has been demonstrated to signiﬁcantly contribute to cardiac
dysfunction in various types of heart disease (20,21). Cardiac hy-
pertrophy is an important compensatory mechanism of the heart
that occurs in response to pathological stresses such as hyperten-
sion, diabetes, myocardial injury or increased cardiac work.
Persistent hypertrophy is associated with cardiac dysfunction.
Previous studies have demonstrated that increased cardiac ﬁbrosis
can induce diastolic dysfunction (22,23). Thus, the improvement of
cardiac hypertrophy and ﬁbrosis by saxagliptin that was observed
in this study might have been responsible for the improved left
ventricular function. Thus, saxagliptin might suppress cardiac
ﬁbrosis through the suppression of cellular phenotypic modulation
by the inhibition of endothelial DPP-4 activity in cardiac tissue,
independently of its glycemic action.
Recent studies have demonstrated that DPP-4 activities in car-
diac tissue were upregulated in experimental models of heart
failure with both cardiac diastolic and systolic dysfunction (24,25).
These ﬁndings suggest that an increase in cardiac DPP-4 activity
may be associated with the development of heart failure. On the
other hand, the present study showed similar levels of cardiac DPP-
4 activity in the normal and control groups of our rat model of
isoproterenol-induced heart failure. In the present study, the
isoproterenol induced cardiac diastolic dysfunction but did not
induced cardiac systolic dysfunction (the decrease of EF and FS). In
rat model of isoproterenol-induced heart failure, histopathological
examination showed that mild or moderate myocardial ﬁbrosis of
left ventricle 2 weeks after the isoproterenol treatment. These
changes of early stage in the present study though to bemilder than
the degrees of injury in the heart failuremodels of previous studies.
Thus, the activities of DPP-4 in cardiac tissue might depend on the
severity of cardiac injury.
DPP-4 is known to cleave a wide range of substrates as well as
incretin hormones, such as NPY, ANP/BNP, SDF-1 and HMGB1.
These substrates have been reported to exert GLP-1-independent
tissue protective effects (26). Shigeta et al. demonstrated that
DPP-4 inhibition exerts a cardioprotective effect via membrane-
bound DPP-4/SDF-1a-dependent action in diabetic rats with dia-
stolic left ventricular dysfunction (27). Furthermore, DPP-4 is
widely expressed on subset of various cell types such as epithelial
cells, macrophage and leukocyte as well as on the endothelial cells.
In addition, DPP-4 is able to interact with proteins such as adeno-
sine deaminase and mannose-6 phosphate/IGF-IIR and is reported
to exhibit functions in the immune response and endothelial cell
damage (28e30). Thus, saxagliptin might also exert car-
dioprotective effects (in part) via GLP-1-independent tissue-
protective actions in rats with heart failure.
In a large scale prospective clinical study, the Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients with Dia-
betes Mellitus (SAVOR TIMI 53) study, saxagliptin did not increase
or reduce the risk for major adverse cardiovascular event (MACE) in
patients with type 2 diabetes, when added to the patients receiving
current standard care (31). However, in SAVOR-TIMI 53 study, an
unexpected increased risk of hospitalization for heart failure was
found in the saxagliptin group. The explanation for this hospitali-
zation for heart failure remains unknown. In the rat model of heart
failure, saxagliptin did not worsen heart failure but exertedcardioprotective effects although the efﬁcacies were restricted. The
clinical effect of saxagliptin might become apparent by evaluating
the effect on early stage of heart failure or bymeasuring biomarkers
and echocardiographic studies in large outcome trials. In addition,
further research needs to investigate the longer-term or reversing
(therapeutic) effects of saxagliptin on heart failure.
In conclusion, the highly potent and tight-binding DPP-4 in-
hibitor saxagliptin inhibited both in situ cardiac DPP-4 activity
staining andmyocardial remodeling, including cardiac hypertrophy
and ﬁbrosis, in rats with isoproterenol-induced heart failure.
Furthermore, saxagliptin ameliorated cardiac diastolic dysfunction
in the isoproterenol-treated rats. Our ﬁndings therefore suggest
that the cardiac DPP-4 inhibition induced by saxagliptin may
ameliorate cardiac diastolic dysfunction via the suppression of
myocardial remodeling in rats with isoproterenol-induced heart
failure.Conﬂicts of interest
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